Update: Molecular radiotherapy: Survey and current status

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 5, 2008, Pages 531-540

  Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha emitters; Lymphoma; MBIG; Radioimmunotherapy; Thyroid cancer

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTINEOPLASTIC AGENT; CHIMERIC ANTIBODY 81C6 AT 211; ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; IBRITUMOMAB TIUXETAN; IODINE 124; LEUKEMIC ANTIBODY HUM195 BI 213; LEXIDRONAM SAMARIUM SM 153; PENTETATE TIN SN 117M; PENTETREOTIDE; RADIOISOTOPE; RADIUM 223; RITUXIMAB; STRONTIUM 89; TOSITUMOMAB I 131; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROLIFERATION; DRUG DOSE ESCALATION; GLIOMA; HUMAN; MOLECULAR RADIOTHERAPY; NEPHROTOXICITY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

ALPHA PARTICLES; ANTINEOPLASTIC AGENTS; HUMANS; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; NEOPLASMS; RADIATION ONCOLOGY; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 55849131053     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0502     Document Type: Review

References (40)

1. Wang WP, Larson SM, Fazzari M, et al. Prognostic value of [F-18]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107.
2. 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45:1366.
3. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anticarcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705.
4. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823.
5. 131 tositumomab) vs. unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL). Blood 2001;98:843A.
6. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10:7792.
7. Dreyling M, Trumper L, von Schilling C, et al. Results of a national consensus workshop: Therapeutic algorithm in patients with follicular lymphoma - role of radioimmunotherapy. Ann Hematol 2007;86:81.
8. Berenson A. 2 Lymphoma Drugs Go Unused, and Backers Cite Market Forces. New York Times 2007 Jul 14;1.
9. Chatal JF, Harousseau JL, Griesinger F, et al. Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, Y-90-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. J Clin Oncol 2004;22:174S.
10. Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4418.
11. Weiner RE, Thakur ML. Radiolabeled peptides in oncology - role in diagnosis and treatment. Biodrugs 2005;19:145.
12. Pasieka JL, Mcewan AJB, Rorstad O. The palliative role of I-131-MIBG and In-111-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004;136:1218.
13. Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children: Current concepts on diagnostic and therapeutic use. J Nucl Med 2005;46:55S.
14. Damerla V, Packianathan S, Boerner PS, et al. Recent developments in nuclear medicine in the management of bone metastases: A review and perspective. Am J Clin Oncol 2005;28:513.
15. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha-particle immunotherapy for myeloid leukemia. Blood 2002;100:1233.
16. Jurcic JG, McDevitt MR, Sgouros G, et al. Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33). Blood 1997;90:2245.
17. 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun 1993;14:121.
18. Zalutsky MR, Cokgor I, Akabani G, et al. Phase I trial of alpha-particle-emitting astatine-211-labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients. Proc Am Assoc Cancer Res 2000;41:544.
19. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451.
20. Hultborn R, Andersson H, Back T, et al. Pharmacokinetics and dosimetry of (211)AT-MX35 F(AB′)(2) in therapy of ovarian cancer - preliminary results from an ongoing phase I study. Cancer Biother Radiopharm 2006;21:395.
21. 211At. Radiat Res 2002;157:633.
22. Kennel SJ, Mirzadeh S. Vascular targeted radioimmunotherapy with 213Bi - an alpha-particle emitter. Nucl Med Biol 1998;25:241.
23. Akabani G, McLendon RE, Bigner DD, et al. Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: Theoretical analysis. Int J Radiat Oncol Biol Phys 2002;54:1259.
24. 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 2002;57:841.
25. Rosenblat TL, McDevitt MR, Pandit-Taskar N, et al. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-HuM195 (Anti-CD33) in acute myeloid leukemia (AML) [abstract]. Proc ASH 2007.
26. Jurcic JG, McDevitt MR, Pandit-Taskar N, et al. Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225. Cancer Biother Radiopharm 2006;21:396.
27. Mulford DA, Pandit-Taskar N, McDevitt MR, et al. Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML). Blood 2004;104:496A.
28. 213Bi-labelled anti-CD19-and anti-CD20-CHX-A ″-DTPA conjugates. Abstr Pap Am Chem Soc 2003;225:U261.
29. Phase I clinical study on alpha-therapy for non-Hodgkin's lymphoma. 04 Jun 28; Dusseldorf, Germany: 2004.
30. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res 2006;12:3843.
31. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005;4:1318.
32. Zalutsky MR, Reardon DA, Akabani G, et al. Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: Phase I study. [abstract] Neuro-oncol 2002;4:S10.
33. Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004;48:289.
34. Bruland OS, Nilsson S, Fisher DR, et al. High-linear-energy transfer irradiation targeted to skeletal metastases by the alpha-emitter Ra-223: Adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12:6250S.
35. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451.
36. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537.
37. 131I-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med 2003;44:260.
38. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S.
39. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46:38S.
40. Kolbert KS, Hamacher KA, Jurcic JG, et al. Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia. J Nucl Med 2001;42:27.